Recursion Pharmaceuticals (RXRX) just delivered encouraging Phase 1b/2 TUPELO data for its FAP drug candidate REC-4881, and that clinical update has quickly reshaped how both Wall Street and ...

Cathie Wood’s ARK Investment Management sharply increased its exposure to AI-driven biotechnology and cryptocurrency during ...

Especially on X, algorithmic culture is characterized by ceaseless iteration: Everything that’s happening is piled atop all ...

The 2026 trading year has kicked into gear, and while some stocks are already pushing higher into the green, others are ...

For decades, software developers have been slipping jokes into their work. One of the most enduring, clever, and geekily satisfying inside jokes has been hiding in plain sight: the recursive acronym.

Biopharma may see a happier year ahead in 2026 than in recent years, according to analysts at William Blair. For one thing, the industry’s top stocks have recovered from lows that stretched into last ...

According to TipRanks.com, Stranahan is a 4-star analyst with an average return of 4.1% and a 52.3% success rate. Stranahan covers the Healthcare sector, focusing on stocks such as Day One ...

The Admiral Twin Drive-In in Tulsa stands as a magnificent time capsule where cinema magic meets starlit Oklahoma skies, drawing movie lovers from Broken Arrow to Bartlesville and beyond. Remember ...

There’s something magical about watching movies under the stars, and the Admiral Twin Drive-In in Tulsa delivers that enchantment with a double dose of nostalgia that’ll make you feel like you’ve time ...

Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its CEO & President, Najat Khan, Ph.D., will present Tuesday, January 13 ...